Core Insights - The "Innovation Drug Industry Special Session" showcased 18 leading biopharmaceutical companies from the Sci-Tech Innovation Board, highlighting their technological breakthroughs and international collaboration strategies [1] - The innovation-driven growth of these companies is evident through significant R&D investments and the successful transition of laboratory results to clinical applications, with 6 new first-class innovative drugs launched in 2024 [2] - The commercialization process is accelerating, with companies experiencing explosive sales growth and improved profitability due to optimized production costs and mature sales systems [3] R&D Investment and Strategies - In 2024, BaiLi Tianheng's R&D investment reached 1.443 billion yuan, a year-on-year increase of over 90%, with 15 candidate drugs in clinical stages and over 80 clinical trials globally [2] - Junshi Bioscience is focusing resources on high-potential projects and exploring next-generation innovative therapies for cancer and autoimmune diseases, with multiple products expected to enter critical registration clinical trials by 2025 [2] - Frontier Biotech is optimizing its pipeline layout based on market needs, focusing on long-acting HIV drugs and new technology RNA drugs, ensuring sustainable development through differentiated competitive advantages [2] Commercialization and Financial Performance - In 2024, Dize Pharmaceutical achieved sales revenue of 360 million yuan, a year-on-year increase of 294.24%, with two products included in the national medical insurance directory [3] - Junshi Bioscience reported a revenue of 1.948 billion yuan in 2024, a 30% increase, with a 44% reduction in net losses, attributed to cost control and resource allocation towards promising R&D projects [4] - Companies are enhancing their global market strategies, with BaiLi Tianheng aiming to become a multinational pharmaceutical company with leading capabilities in tumor treatment by 2028 [4][5]

Investment Rating - The investment rating for the company is "Accumulate" [6] Core Views - The company is expected to see a profit turning point due to high profitability and gradual release of profit elasticity. The gross profit margin for 2024 is projected at 70.22%, a year-on-year decrease of 7.85 percentage points, primarily due to the lower margin impact from the consolidation of Fuli Instruments. The core products, chromatography fillers and chromatography media, maintain a gross profit margin of 81.56%, with a slight year-on-year decline of 2.39 percentage points. The company’s unique ability to self-produce core raw materials, microspheres, is expected to further highlight its competitive edge, supporting a high level of gross margin for core products [2][4]. Financial Performance - In 2024, the company achieved revenue of 782 million yuan, a year-on-year increase of 33.33%. The net profit attributable to the parent company was 82.84 million yuan, up 20.82% year-on-year. In Q1 2025, the company reported revenue of 189 million yuan, a year-on-year growth of 22.39%, and a net profit of 29.22 million yuan, reflecting a 72.98% increase year-on-year [9][11]. Growth Potential - The company is positioned to benefit from accelerated domestic substitution and its own product strength and platform-driven growth. The core business of chromatography fillers and chromatography media is expected to continue its growth trend, with Q1 2025 revenue reaching approximately 111 million yuan, a year-on-year increase of about 10.62%. The strategic focus on high-quality clients is anticipated to further enhance operational quality [4][9]. Earnings Forecast and Valuation - The company’s revenue is projected to reach 966 million yuan in 2025, with a year-on-year growth of 23.44%. The net profit attributable to the parent company is expected to be 139 million yuan, reflecting a significant year-on-year increase of 68.00%. The earnings per share (EPS) for 2025 is estimated at 0.34 yuan, with a price-to-earnings (P/E) ratio of 66 times based on the closing price on May 8, 2025 [4][11].

Investment Rating - The investment rating for the company is "Accumulate" [6] Core Views - The company is expected to see a profit turning point due to high profitability and gradual release of profit elasticity, despite a slight decline in gross margin to 70.22% in 2024 [2] - The company has a strong cash flow generation capability, with a net cash flow from operating activities of 133 million yuan in 2024, indicating good operational quality [3] - The company is positioned to benefit from domestic substitution trends and has built a unique "product + service" platform, which is expected to drive growth in the coming years [4] Summary by Sections Profitability - The gross margin for 2024 is projected at 70.22%, down 7.85 percentage points year-on-year, primarily due to the lower margin impact from the consolidation of Fuli Instruments. The core products, chromatography fillers and chromatography media, maintain a gross margin of 81.56%, with a slight year-on-year decline of 2.39 percentage points [2] - The company’s high R&D investment has led to a sufficient reserve of new products, which can help mitigate risks from intensified market competition [2] Operational Quality - The net cash flow from operating activities for 2024 is expected to be 133 million yuan, reflecting a year-on-year increase of 5.99%, indicating sustained operational quality [3] - The accounts receivable turnover days for 2024 are 117 days, shortened by approximately 14 days year-on-year, while the first quarter of 2025 shows an increase to 145 days, likely due to a higher proportion of longer-term instrument products [3] Earnings Forecast and Valuation - The company is expected to achieve revenues of 966 million yuan in 2025, growing by 23.44% year-on-year, and a net profit attributable to shareholders of 139 million yuan, representing a growth of 68.00% [4] - The projected earnings per share (EPS) for 2025 is 0.34 yuan, with a price-to-earnings (P/E) ratio of 66 times based on the closing price on May 8, 2025 [4]

Group 1 - The company reported a revenue of 782 million yuan for 2024, representing a year-on-year growth of 33.33%, with a net profit attributable to the parent company of 83 million yuan, up 20.82% year-on-year [1] - In Q1 2025, the company achieved a revenue of 189 million yuan, a year-on-year increase of 22.39%, and a net profit attributable to the parent company of 29 million yuan, up 72.98% year-on-year [1] - The core business of chromatography fillers and media generated a revenue of 451 million yuan in 2024, with a year-on-year growth of 10.20% [2] Group 2 - The newly added chromatography analysis instruments and accessories contributed a revenue of 154 million yuan, primarily from the consolidation of the acquired company Fuli Instruments [2] - The market for chromatography fillers is expanding, with a current domestic market penetration rate of only about 10%, indicating significant potential for domestic substitution [3] - The company has established strategic cooperation agreements with five major clients, resulting in a sales volume of 224 million yuan, accounting for 50% of the revenue from chromatography fillers [3] Group 3 - The company is evolving into a leading domestic supplier of chromatography fillers, consumables, and instruments, driven by underlying technology [4] - Revenue projections for 2025-2027 are 977 million yuan, 1.17 billion yuan, and 1.37 billion yuan, with net profits of 134 million yuan, 203 million yuan, and 290 million yuan respectively [4] - The current stock price corresponds to a PE ratio of 67, 45, and 31 times for 2025-2027 [4]

Core Viewpoint - Nanwei Technology has been covered for the first time with a "Buy" rating and a target price of 29.2 yuan, indicating strong growth potential in the domestic market for chromatography materials and instruments [1]. Financial Performance - In 2024, the company achieved revenue of 782 million yuan, a year-on-year increase of 33.33%, and a net profit attributable to shareholders of 83 million yuan, up 20.82%. The non-recurring net profit was 66 million yuan, showing a significant growth of 108.55% [2]. - For Q1 2025, the company reported revenue of 189 million yuan, a year-on-year increase of 22.39%, and a net profit attributable to shareholders of 29 million yuan, up 72.98%. The non-recurring net profit was 25 million yuan, reflecting an 85.28% increase [2]. Business Segments - The core business of chromatography fillers and media generated revenue of 451 million yuan in 2024, a growth of 10.20%. The revenue from large molecule chromatography media was 249 million yuan, flat year-on-year, while small molecule chromatography fillers saw a 16.13% increase to 165 million yuan [3]. - The newly added chromatography analysis instruments and accessories contributed 154 million yuan, primarily from the acquisition of Fuli Instruments. Revenue from protein chromatography systems and accessories decreased by 33.41% to 40 million yuan, while liquid chromatography columns and sample pretreatment products increased by 26.15% to 73 million yuan [3]. Market Dynamics - The chromatography filler market is expanding, driven by the growth of biopharmaceuticals and peptide drugs. Currently, the market is dominated by imported manufacturers, with domestic market share at only about 10%. The emphasis on cost reduction and supply chain security is accelerating domestic substitution [4]. - The company has established a comprehensive product layout and has gained recognition from leading domestic pharmaceutical companies. In 2024, the number of customers increased to 792, with strategic cooperation agreements signed with five new clients [4]. Investment Outlook - The company is evolving into a leading domestic supplier of chromatography fillers, consumables, and instruments, benefiting from ongoing domestic substitution and a robust project pipeline. Revenue projections for 2025-2027 are 977 million, 1.17 billion, and 1.37 billion yuan, with net profits of 134 million, 203 million, and 290 million yuan respectively [5].

中信证券股份有限公司 关于苏州纳微科技股份有限公司 2024 年度持续督导工作现场检查报告 根据《上海证券交易所上市公司自律监管指引第 11 号——持续督导》等有 关法律、法规的规定，中信证券股份有限公司（以下简称"中信证券"或"保荐 人"）作为正在对苏州纳微科技股份有限公司（以下简称"纳微科技""公司" "上市公司"）进行持续督导工作的保荐人，对 2024 年度（以下简称"本持续 督导期间"）的规范运作情况进行了现场检查，现就现场检查的有关情况报告如 下： 一、本次现场检查的基本情况 （一）保荐人 中信证券股份有限公司 （二）保荐代表人 王琦、王栋 （三）现场检查人员 王琦、楚合玉 （四）现场检查时间 2025 年 4 月 25 日 现场检查人员对本持续督导期内公司治理和内部控制情况、信息披露情况、 公司的独立性以及与控股股东、实际控制人及其他关联方资金往来情况、募集资 金使用情况、关联交易、对外担保、重大对外投资情况、经营状况等方面进行了 现场检查，具体检查内容详见本报告"二、本次现场检查主要事项及意见"。 1 （六）现场检查手段 本次现场检查的手段主要包括资料查阅、访谈、现场查看等，具体检查手段 详见" ...

苏州纳微科技股份有限公司 2024 年年度股东大会会议资料 证券代码：688690 证券简称：纳微科技 苏州纳微科技股份有限公司 2024年年度股东大会 2024 年年度股东大会会议须知 1 苏州纳微科技股份有限公司 2024 年年度股东大会会议资料 会议资料目录 | 2024 年年度股东大会会议须知 3 | | | --- | --- | | 2024 年年度股东大会会议议程 5 | | | 一、会议时间、地点及投票方式 | 5 | | 二、会议议程 | 5 | | 2024 年年度股东大会会议议案 7 | | | 议案一：关于公司《2024 年年度报告》及摘要的议案 7 | | | 议案二：关于公司 2024 年度财务决算报告和 2025 年度财务预算报告的议案 | 8 | | 议案三：关于公司 2024 年度董事会工作报告的议案 | 11 | | 议案四：关于公司 2024 年度监事会工作报告的议案 | 22 | | 议案五：关于公司 2024 年度独立董事述职报告的议案 | 28 | | 议案六：关于公司 2024 年度利润分配方案的议案 | 29 | | 议案七：关于确认 2024 年度日常关联交易 ...

Summary of the Conference Call Industry Overview - The pharmaceutical sector is experiencing a resurgence driven by strong domestic and foreign demand, with the innovative drug segment performing particularly well. The recovery of medical insurance policies and limited impact from Sino-US trade tensions have contributed to this positive trend. Institutional holdings have notably increased [1][4][5]. Key Points and Arguments - **Innovative Drugs**: The innovative drug sector is recommended for overweight allocation due to strong demand and supply dynamics. Companies in this segment have shown better-than-expected performance, supported by favorable policy changes [1][10]. - **Medical Devices**: The electrophysiology and orthopedic consumables sectors are highlighted as areas of strong performance. Orthopedic consumables benefit from a low base and domestic substitution, while electrophysiology maintains stable growth [1][6]. - **CXO Sector**: The CXO sector has shown robust performance, with companies like Kangde Biological and LianTuo Biological reporting impressive results. The first quarter results indicate a strong growth momentum, making this sector a viable investment option [1][7]. - **Consumer Healthcare**: Overall performance in consumer healthcare is lukewarm, but leading companies like Aier Eye Hospital and JD Health have exceeded expectations, demonstrating their ability to gain market share amid a consumption downturn [1][8]. - **Upstream Supply Chain**: While overall performance in the upstream supply chain is not as strong as in innovative drugs, companies like Baipusais and Nawei Technology have shown significant competitive advantages, increasing their market share during the industry downturn [1][9]. Additional Important Insights - **Market Performance in April 2025**: The pharmaceutical sector had a lackluster performance in April, with the Shanghai Composite Index down 1.7% and the Shenwan Pharmaceutical Index down 2.1%. Notable gainers included Yipin Hong and Yong'an Pharmaceutical, both up 56% [3]. - **Investment Strategy**: The strategy suggests overweighting innovative drugs and gradually increasing allocation to reasonably valued CXO companies. Individual stock selection is recommended for consumer and upstream supply chain investments [1][10][12]. - **Monthly Portfolio Changes**: The May 2025 portfolio includes large-cap pharmaceutical stocks such as Heng Rui Pharmaceutical and BeiDa Pharmaceutical, reflecting positive changes in their fundamentals and strong R&D capabilities [2][13]. - **Rationale for Large-Cap Stocks**: The focus has shifted to larger companies due to their improved fundamentals and strong R&D capabilities, as smaller companies have already seen significant price increases [14]. - **Specific Company Recommendations**: - **Heng Rui Pharmaceutical**: Leading in R&D among traditional large enterprises, with over 100 projects in development [15]. - **Hua Dong Pharmaceutical**: Valued at approximately 16 times earnings, with a promising transition and sales growth expected [16]. - **BeiDa Pharmaceutical**: Expected to adopt more collaborative R&D approaches, making it a valuable investment at current valuations [17]. - **Xinda**: Anticipated revenue growth from 1.4 billion to 2.4 billion, with a favorable outlook due to policy improvements [18]. - **Kelong Biotechnology**: Notable performance in clinical trials, making it a strong candidate for investment [19]. - **Xinda**: Projected revenue of 40 billion in Q1, with a strong annual forecast [20]. - **Rongchang Biological**: Long-term tracking with good overseas positioning [21]. - **CXO Companies**: Notable mentions include WuXi AppTec and WuXi Biologics, recognized for their solid fundamentals [22].

Core Viewpoint - The 18th China Scientific Instrument Development Annual Conference (ACCSI 2025) will be held from May 11 to 13, 2025, in Shanghai, focusing on the theme "Digital Intelligence Drives New Quality Leadership" [1][2]. Group 1: Conference Overview - ACCSI is positioned as a high-level industry summit for the scientific instrument sector, having successfully held 17 sessions with attendance exceeding 1,500 participants, earning the title of the "Davos Forum" for the scientific instrument industry [2]. - The conference aims to summarize the latest developments in the Chinese scientific instrument industry over the past year, presenting new industry development policies, market demand information, and technological advancements to attendees [2]. - Key industry figures, including government leaders, experts, CEOs, and investment institution heads, will provide strategic decision-making references through various formats such as reports, dialogues, and discussions [2]. Group 2: Event Schedule - The main conference will take place on May 12, 2025, from 09:00 to 11:20 at the Fuyue Hall 1+2+3 [6]. - The 6th Scientific Instrument CMO Summit Forum is scheduled for May 11, 2025, from 13:30 to 17:30 at Fuyue Hall 3 [2]. - Various specialized forums and roadshows will be held throughout the conference, focusing on topics such as high-end scientific instruments, artificial intelligence integration, and investment opportunities in the scientific instrument sector [19][20][25]. Group 3: Key Topics and Discussions - The conference will feature discussions on the development and application of hyperspectral and imaging technologies, quantum technology, and the strategic layout of companies like Shimadzu in the context of Chinese opportunities [7]. - A series of roadshows will showcase innovative projects, including automated micro-nano optical chip testing systems and advanced imaging platforms [15][19]. - The integration of artificial intelligence in scientific instruments will be a significant focus, with forums dedicated to exploring AI's role in driving innovation and transformation within the industry [24][25]. Group 4: Networking and Collaboration - The conference will facilitate networking opportunities among industry professionals, fostering collaboration between academia, industry, and government to enhance the scientific instrument ecosystem [2][19]. - The event will also include award ceremonies recognizing high-potential companies in the scientific instrument sector for the year 2024 [16]. Group 5: Future Directions - The conference aims to address the future trends and investment opportunities in high-end scientific instruments, emphasizing the importance of innovation and market adaptability [16][19]. - Discussions will also cover the digital transformation of the scientific instrument after-market services, focusing on proactive maintenance and user demand responsiveness [60].

2025 年 4 月 29 日 晨会速递 分析师点评 市场数据 总量研究 【金融工程】各类行业主题基金普遍上涨，被动资金显著加仓黄金 ETF——基金市场 与 ESG 产品周报 20250428 本周权益型基金净值明显上涨，中长期纯债型基金业绩小幅回调；各类行业主题基金 均呈现上涨，新能源主题基金表现占优，上涨 2.76%。股票型 ETF 资金呈现净流出， 大盘宽基 ETF 为资金流出的主要方向，黄金 ETF 为代表的商品型 ETF 资金流入超百 亿。从主动资金行业配置动向看，有色金属、电子、银行等行业获主动资金增配。 【金融工程】市场波动温和提升，杠铃组合或占优——金融工程市场跟踪周报 20250428 上周 A 股窄幅震荡，市场整体表现不佳。主要宽基指数量能维持近期低位，量能择时 指标仍维持谨慎信号。资金面方面，ETF 资金周度净流出，大盘宽基 ETF 为净流出主 要方向。市场波动方面，主要宽基指数截面波动率、时序波动率环比上周皆有上升。 行业研究 【环保】25 年新增核准 10 台核电机组，可控核聚变领域近期频现突破——碳中和领 域动态跟踪（一百五十七）(买入) 我国核电项目审批已经进入规模化核准阶段。" ...